KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
November 06 2018 - 7:30AM
Business Wire
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage
pharmaceutical company focused on the discovery, development, and
commercialization of small molecule protease inhibitors, today
announced that it will present a corporate overview at the
following upcoming investor conferences:
- Stifel 2018 Healthcare Conference on
Tuesday, November 13, 2018 at 10:15 a.m. EST in New York, NY;
- Jefferies London Healthcare Conference
on Thursday, November 15, 2018 at 8:40 a.m. GMT in London,
England.
A live webcast of the presentations may be accessed on the
Investors section of the Company’s website at www.kalvista.com. An
audio archive will be available on KalVista’s website for 30 days
following the presentations.
About KalVista Pharmaceuticals, Inc.KalVista
Pharmaceuticals, Inc. is a pharmaceutical company focused on the
discovery, development, and commercialization of small molecule
protease inhibitors for diseases with significant unmet need. The
initial focus is on inhibitors of plasma kallikrein, which is an
important component of the body’s inflammatory response and which,
in excess, can lead to increased vascular permeability, edema and
inflammation. KalVista has developed a proprietary portfolio of
novel, small molecule plasma kallikrein inhibitors initially
targeting hereditary angioedema (HAE) and diabetic macular edema
(DME). The Company has created a structurally diverse portfolio of
oral plasma kallikrein inhibitors and is advancing multiple drug
candidates into Phase 1 clinical trials for HAE. The Company has
selected KVD900 as its program to be advanced as an on-demand
therapy for acute HAE attacks, and anticipates commencing a Phase 2
proof-of-concept study in HAE patients in late 2018. In DME,
KalVista’s most advanced program, an intravitreally administered
plasma kallikrein inhibitor known as KVD001, began a Phase 2
clinical trial in 2017 that is anticipated to report data in the
second half of 2019.
For more information, please visit www.kalvista.com.
Forward-Looking StatementsThis press release contains
"forward-looking" statements within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by words such
as: "anticipate," "intend," "plan," "goal," "seek," "believe,"
"project," "estimate," "expect," "strategy," "future," "likely,"
"may," "should," "will" and similar references to future periods.
These statements are subject to numerous risks and uncertainties
that could cause actual results to differ materially from what we
expect. Examples of forward-looking statements include, among
others, future clinical trial timing and results. Further
information on potential risk factors that could affect our
business and its financial results are detailed in the annual
report on Form 10-K filed on July 30, 2018 and other reports as
filed from time to time with the Securities and Exchange
Commission. We undertake no obligation to publicly update any
forward-looking statement, whether written or oral, that may be
made from time to time, whether as a result of new information,
future developments or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181106005434/en/
KalVista Pharmaceuticals, Inc.Leah Monteiro,
857-999-0808Director, Corporate Communications & Investor
Relationsleah.monteiro@kalvista.com
KalVista Pharmaceuticals (NASDAQ:KALV)
Historical Stock Chart
From Mar 2024 to Apr 2024
KalVista Pharmaceuticals (NASDAQ:KALV)
Historical Stock Chart
From Apr 2023 to Apr 2024